Effectiveness of infliximab (tumor necrotising factor-alpha antagonist) in the treatment of late-onset depressive spectrum disorder in patients of 60 years and above

Not Applicable

Completed

• Conditions: Depressive disorders; Mental and Behavioural Disorders; Depression

• Registration Number: ISRCTN65900535
• Lead Sponsor: eiden University Medical Center (LUMC) (The Netherlands)

Brief Summary

2010 Results article in https://pubmed.ncbi.nlm.nih.gov/20473080/ (added 05/08/2021)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-12-28
• Study Completion: 2007-11-30
• Last Update Posted: 17 August 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 50

Inclusion Criteria

1. Patients with depressive spectrum disorders (dysthymia, minor and major depression) using Standardised Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders Fourth edition (DSM-IV) disorders
2. Age more than 60 years
3. Late onset of depressive spectrum disorder (age more than 55 years)
4. Resistant to at least one regular antidepressant drug, used for at least six weeks and in sufficient doses; or suffering from too many side effects of the antidepressant

Exclusion Criteria

1. Psychotic features
2. Bipolar disorder
3. Severe suicidal thoughts or actions
4. Serious infectious diseases
5. (Suspicion of) tuberculosis
6. Serious cardiac failure
7. Prior treatment with recombinant antibodies
8. Allergy to infliximab
9. Mini Mental State Examination (MMSE) less than or equal to 22/30
10. Insufficient knowledge of the Dutch language

Study & Design

• Study Type: Interventional
• Study Design: Not specified